Join CNETS Canada 2019 National NET Patient Conference's video & audio conference by clicking the following link: https://freeman.meetngreet.ca/join/x1GxoRj3UO 2019 NATIONAL NET PATIENT CONFERENCE LIVE-STREAM Saturday April 6, 2019 from [...]
As we start 2019 we bid farewell to a long-time board member and welcome three new board members to CNETS Canada’s Board of Directors. We extend our heartfelt gratitude to [...]
Our very own Jackie Herman, CNETS Canada President was elected to the International Neuroendocrine Cancer Alliance (INCA) on January 30th, 2019. INCA welcomed 2 new Directors to the INCA [...]
November 10, 2018 - Toronto's CN Tower lights up black & white in honour of NET Cancer Awareness Day
Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1) "XERMELOTM is a novel, orally administered, inhibitor of the enzyme tryptophan hydroxylase [...]
The latest edition of the ePatient magazine has several articles that focus on Neuroendcorine Tumours (NETs). Check it out at: ePatient Magazine
Caprelsa (vandetanib) is indicated for the treatment of symptomatic or progressive Medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease. Alberta Health Services has put the [...]
TELOTRISTAT is an adjunct to somatostatin analogue therapy for the long-term treatment of carcinoid syndrome to improve symptom control in adult patients with metastatic neuroendocrine tumours.The company who makes telotristat [...]
RESEARCH ARTICLE A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal Published in Modern Pathology [...]
RIP THE GREAT ARETHA FRANKLIN Aretha Franklin, the Queen of Soul, passed away from neuroendocrine cancer (NETs) of the pancreas, the very same cancer that killed Apple [...]